Cost effectiveness of combination therapy with Pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective

Pioglitazone has been approved in Europe for oral combination therapy for type 2 diabetes mellitus. Along with other agents of the thiazolidinedione class, it has a novel intracellular mechanism of action. Clinical trials with pioglitazone have confirmed a strong product profile in terms of control...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2004-01, Vol.22 (5), p.321-341
Hauptverfasser:	NEESER, Kurt, LUBBEN, Georg, SIEBERT, Uwe, SCHRAMM, Wendelin
Format:	Artikel
Sprache:	eng
Schlagworte:	Acarbose Antilipemic agents Biological and medical sciences Blood sugar Cost-Benefit Analysis Cost-effectiveness Decision-making Diabetes Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Diabetes therapy Diabetes. Impaired glucose tolerance Drug Therapy, Combination Endocrine pancreas. Apud cells (diseases) Endocrinopathies Germany Health care industry Health technology assessment Hormones. Endocrine system Humans Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Lipids Management. Various non-drug treatments. Langerhans islet grafts Markov Chains Markov processes Medical sciences Metformin Pharmacology. Drug treatments Pioglitazone Sulfonylureas Thiazolidinediones Thiazolidinediones - economics Thiazolidinediones - therapeutic use Type 2 diabetes Type-2-diabetes-mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!